1.Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea.
Gebra Cuyun CARTER ; Anna KALTENBOECK ; Jasmina IVANOVA ; Astra M LIEPA ; Alexandra SAN ROMAN ; Maria KOH ; Narayan RAJAN ; Rebecca CHENG ; Howard G BIRNBAUM ; Jong Seok KIM ; Yung Jue BANG
Cancer Research and Treatment 2017;49(3):578-587
PURPOSE: The purpose of this study was to understand patient treatment patterns, outcomes, and healthcare resource use in cases of metastatic and/or locally recurrent, unresectable gastric cancer (MGC) in South Korea. MATERIALS AND METHODS: Thirty physicians reviewed charts of eligible patients to collect de-identified data. Patients must have received platinum/fluoropyrimidine first-line therapy followed by second-line therapy or best supportive care, had no other primary cancer, and not participated in a clinical trial following MGC diagnosis. Data were summarized using descriptive statistics. Kaplan-Meier analysis was used to describe survival. RESULTS: Of 198 patients, 73.7% were male, 78.3% were diagnosed with MGC after age 55 (mean, 61.3 years), and 47.0% were current or former smokers. The majority of tumorswere located in the antrum/pylorus (51.5%). Metastatic sites most often occurred in the peritoneum (53.5%), lymph nodes (47.5%), and liver (38.9%). At diagnosis, the mean Charlson comorbidity indexwas 0.4 (standard deviation, 0.6). The most common comorbidities were chronic gastritis (22.7%) and cardiovascular disease (18.7%). Most patients (80.3%) received second-line treatment. Single-agent fluoropyrimidine was reported for 22.0% of patients, while 19.5% were treated with irinotecan and a fluoropyrimidine or platinum agent. The most common physician-reported symptoms during second-line treatment were nausea/vomiting (44.7%) and pain (11.3%), with antiemetics (44.7%), analgesics (36.5%), and nutritional support (11.3%) most often used as supportive care. Two-thirds of inpatient hospitalizations were for chemotherapy infusion. Outpatient hospitalization (31.6%) and visits to the oncologist (58.8%) were common among second-line patients. CONCLUSION: Most patients received second-line treatment, although regimens varied. Understanding MGC patient characteristics and treatment patterns in South Korea will help address unmet needs.
Analgesics
;
Antiemetics
;
Cardiovascular Diseases
;
Comorbidity
;
Delivery of Health Care
;
Diagnosis
;
Drug Therapy
;
Gastritis
;
Hospitalization
;
Humans
;
Inpatients
;
Kaplan-Meier Estimate
;
Korea*
;
Liver
;
Lymph Nodes
;
Male
;
Nutritional Support
;
Observational Study
;
Outpatients
;
Peritoneum
;
Platinum
;
Republic of Korea
;
Stomach Neoplasms*